Tags : Generics

PhaseBio Reports First Patients Dosing in its P-III REVERSE-IT Study

Shots: The company has reported the expansion of its P-III REVERSE-IT study for bentracimab in Canada where the first patients from major health centers globally have been enrolled (approx. 200 patients) and dosed Bentracimab demonstrated sustained reversal of the antiplatelet activity of Brilinta (ticagrelor). In a translational study, bentracimab achieved equivalent reversal of branded ticagrelor […]Read More

Zentiva to Acquire Alvogen’s Generics and OTC Business in Central

Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be closed in Q1’20 The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen […]Read More

WHO Signs MoU with IGBA for Promoting the Access to

Shots: The memorandum of understanding signed between WHO and International Generic and Biosimilar Medicines Association to facilitates the approval of generics and biosimilars thus reduces the burden of clinical trials for biosimilars and increases the access to drugs The WHO’s efforts to increase the access to Biosimilar includes List of International Comparators, providing information on […]Read More